Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743853 | 0.92 | NPC1 (0.36) | PPARDPPARAFFAR1CHRM5SLC6A3 | |
| SCHEMBL3747892 | 0.90 | PLA2G2A (0.42) | PPARDPPARAPLA2G2AFFAR1CHRM5 | |
| SCHEMBL3756351 | 0.85 | PPARD (0.36) | PPARDPPARAPLA2G2APLA2G10PLA2G1B | |
| SCHEMBL3753667 | 0.84 | PPARD (0.36) | PPARDPPARAFFAR1CHRM5SLC6A3 | |
| SCHEMBL3743772 | 0.82 | PPARD (0.38) | PPARDPPARAFFAR1NPC1ALDH1A1 | |
| SCHEMBL3526099 | 0.82 | BPGM (0.33) | PPARDPPARAPLA2G2AALDH1A1PLA2G10 | |
| SCHEMBL3529025 | 0.82 | PTGES (0.33) | — | |
| SCHEMBL3532780 | 0.82 | PPARG (0.36) | PPARDPPARAPLA2G2APLA2G10PLA2G1B | |
| SCHEMBL3743848 | 0.81 | PPARD (0.38) | PPARDPPARAFFAR1 | |
| SCHEMBL3742785 | 0.81 | PPARD (0.43) | PPARDPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| EP-1931660-B1 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-7834030-B2 | Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1931660-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262036-A1 | Phenyl-[1,2,4]-oxadiazol-5-one Derivatives, Pharmaceutical Compositions and Therapeutic Use Thereof | GPR119, CPT1A, PC | PPARD 63/4885PPARA 87/4885PLA2G2A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.